ADC Therapeutics

ADCT

Market cap $432M

Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth.

ADC Therapeutics SA remains a Strong Buy, driven by pivotal ZYNLONTA combination trials targeting 2nd-line r/r DLBCL. Topline data from the phase 3 LOTIS-5 trial (ZYNLONTA + rituximab) is expected in Q2 2026, representing a major inflection point. ZYNLONTA + glofitamab in phase 1b LOTIS-7 achieved an 89.8% ORR and 77.6% CR rate, with further data expected by the end of 2026.

ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.36 per share a year ago.

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end First quarter 2026 net product revenue of $20.0 million Cash and cash equivalents of $231.0 million as of March 31, 2026, with an expected cash runway at least into 2028 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, May 4, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the first quarter ended March 31, 2026, and provided recent operational updates.

Here is how ADC Therapeutics SA (ADCT) and Bioventus (BVS) have performed compared to their sector so far this year.

LAUSANNE, Switzerland, May 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 49,400 of the Company's common shares to two new employees on May 1, 2026 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.

LAUSANNE, Switzerland, April 27, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Monday, May 4, 2026, at 8:30 a.m. EDT to report financial results for the first quarter of 2026 and provide operational updates.

Here is how ADC Therapeutics SA (ADCT) and Biogen Inc. (BIIB) have performed compared to their sector so far this year.

LAUSANNE, Switzerland, April 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on April 1, 2026 ("Grant"). The Grant was offered as material inducement to the employee's employment.